MEOHP was associated with the lowest breast cancer recurrence risk in the status of ER-positive, PR-negative, and HER2-negative (molecular subtype of breast cancer: luminal A) and the dose–response was U-shaped. This evidence concerns the gene PGR and breast carcinoma.